
The doctor prescribed favipiravir to the baby boy. However, 18 hours later, the baby’s mother noticed that his eyes had changed color.
In an unusual instance of a medical side effect, the brown colour of the eyes of a 6-month-old boy in Thailand turned a deep indigo-blue colour after he was given the antiviral Favipiravir to treat COVID-19.
As per reports, the baby was diagnosed with COVID-19 after having a fever and cough for a day. He was treated with favipiravir, an antiviral medication, for 3 days. The treatment helped improve his COVID symptoms, but his mother noticed that his eye colour had changed from dark brown to bright blue just 18 hours after he started taking the medication.
The doctor stopped the treatment after seeing the colour change, which returned to its original brown colour 5 days after favipiravir was stopped.
“No bluish discolouration was observed in other areas such as skin, nails, or oral and nasal mucosa. Symptoms improved after 3 days of favipiravir therapy. The paediatrician advised that the patient discontinue therapy because of favipiravir-induced corneal discolouration. The cornea returned to normal colour on Day 5 after stopping the medicine,” the authors of the medical report said.
Favipiravir: All You Need To Know About This COVID-19 Medicine
Favipiravir is an antiviral medication that works by blocking the virus that causes COVID-19 from wreaking havoc inside the body. The medicine was originally developed to treat the common cold and influenza, but it is also being used to treat COVID-19. The dosage of this medicine completely depends on the severity of the infection, however, as per the developers, Favipiravir should be taken as a pill twice a day for 5 days. As of date, this medicine is approved for use to treat COVID-19 in Japan, China, and India, and it is also being evaluated in clinical trials in other countries.
The effectiveness of favipiravir in treating COVID-19 is still being studied. Some studies have shown that it may help to reduce the severity of symptoms and the risk of hospitalization, but other studies have not found a significant benefit.
window.addEventListener(‘load’, (event) => {
$(‘#commentbtn’).on(“click”,function(){
(function(d, s, id) { var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) return; js = d.createElement(s); js.id = id; js.src = “//connect.facebook.net/en_US/sdk.js#xfbml=1&version=v2.3”; fjs.parentNode.insertBefore(js, fjs);}(document, ‘script’, ‘facebook-jssdk’));
$(“.cmntbox”).toggle();
});
});